Shopping Cart 0
Cart Subtotal
AED 0

Callitas Therapeutics Inc (LILY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Callitas Therapeutics Inc (Callitas Therapeutics), formerly M Pharmaceutical Inc, is a drug discovery and development company that offers ground-breaking drug treatments and biomedical technologies. The company's products include weight management products, infertility products and women's healthcare products. It also provides comprising ToConceive, C-103 Reformulated Orlistat and Extrinsa. Callitas Therapeutics' products are used to improve the lives of people facing obesity, infertility and intimacy issues. The company's ToConceive is a fertility enhancing moisturizer that increases woman's own natural conception lubrication called transudate to aid in conception and Extrinsa address the lack of female sexual dysfunction solutions and focus on women with orgasm and arousal difficulties. Its topical, local, and non-systemic product is also non-hormonal and does not affect the central nervous system. Callitas Therapeutics is headquartered in Vancouver, British Columbia, Canada.

Callitas Therapeutics Inc (LILY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Callitas Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

M Pharma Acquires Assets from 40J's 12

M Pharma Acquires Orlistat Assets from Chelatexx 13

Partnerships 14

Callitas Health Enters into Partnership with NFI Consumer Healthcare 14

M Pharma to Form Joint Venture 15

Licensing Agreements 16

Callitas Health Recieves Intellectual Property from Ronald J. Thompson 16

M Pharma Enters into Licensing Agreement for Pediatric Orphan Drug 17

Equity Offering 18

M Pharma Raises USD0.03 Million in Private Placement of Units 18

M Pharma Raises USD0.7 Million in Private Placement of Units 19

M Pharma to Raise USD0.3 Million in Private Placement of Units 20

M Pharma Raises USD0.86 Million in Private Placement of Units 21

M Pharma Raises USD1 Million in Private Placement of Units 22

Acquisition 23

M Pharma Acquires ToConceive 23

M Pharma Plans to Acquire Pharma Company with an FDA Approved Women's Health Product 24

M Pharma Acquires Trimtec Biomedical 25

M Pharma Acquires RX Global Capital for USD1.9 Million 26

Callitas Therapeutics Inc-Key Competitors 27

Callitas Therapeutics Inc-Key Employees 28

Callitas Therapeutics Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Corporate Communications 30

Jun 07, 2018: James Thompson Elevated to President and Chief Executive Officer of Callitas Health 30

Jan 03, 2018: Callitas Announces New Interim CEO 31

Jun 08, 2017: M Pharmaceutical Appoints New Chief Financial Officer 32

Mar 03, 2017: M Pharmaceutical Appoints Kim Whittemore of San Diego, California to Its Board of Directors 33

Feb 21, 2017: M Pharmaceutical Appoints Mr. William A. Rodgers Jr., of Milton, Georgia to Its Board of Directors 34

Feb 13, 2017: M Pharmaceutical Appoints Mr. Gary Thompson President & CEO 35

Product News 36

Sep 29, 2017: ToConceive launches new paraben-free formula to promote natural conception 36

07/14/2017: M Pharmaceutical Provides Update on Extrinsa 37

Jan 24, 2017: M Pharmaceutical Announces Strategy To Seek Distribution Partners For Their Patented Technologies To Deliver Phytoestrogens For The Treatment Of The Symptoms Of Menopause 38

Jan 12, 2017: M Pharmaceutical Announces Plans to Develop a Drug Product for Treatment of Female Sexual Dysfunction 39

Product Approvals 40

Oct 11, 2017: Callitas Announces Positive FDA Response to Extrinsa Pre-IND Submission 40

Jul 18, 2017: M Pharmaceutical Plans to Submit Extrinsa PIND Meeting Request Letter and Package to US FDA 41

Other Significant Developments 42

Apr 19, 2018: Callitas Health Releases Annual Update Letter to Shareholders 42

Mar 13, 2018: Callitas Health Announces Selection Of TraDigitalIR As Investor And Public Relations Advisor 44

Mar 01, 2018: Callitas Health Has Big Plans For Broad Product Portfolio 45

Sep 15, 2017: M Pharmaceutical Announces Name Change to Callitas Health and Share Consolidation 47

Aug 01, 2017: M Pharmaceutical USA Announces a Change of Name to Callitas Therapeutics 48

Jul 07, 2017: M pharmaceutical reforecasts 2017 and 2018 revenues upward 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Callitas Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Callitas Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Callitas Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

M Pharma Acquires Assets from 40J's 12

M Pharma Acquires Orlistat Assets from Chelatexx 13

Callitas Health Enters into Partnership with NFI Consumer Healthcare 14

M Pharma to Form Joint Venture 15

Callitas Health Recieves Intellectual Property from Ronald J. Thompson 16

M Pharma Enters into Licensing Agreement for Pediatric Orphan Drug 17

M Pharma Raises USD0.03 Million in Private Placement of Units 18

M Pharma Raises USD0.7 Million in Private Placement of Units 19

M Pharma to Raise USD0.3 Million in Private Placement of Units 20

M Pharma Raises USD0.86 Million in Private Placement of Units 21

M Pharma Raises USD1 Million in Private Placement of Units 22

M Pharma Acquires ToConceive 23

M Pharma Plans to Acquire Pharma Company with an FDA Approved Women's Health Product 24

M Pharma Acquires Trimtec Biomedical 25

M Pharma Acquires RX Global Capital for USD1.9 Million 26

Callitas Therapeutics Inc, Key Competitors 27

Callitas Therapeutics Inc, Key Employees 28

Callitas Therapeutics Inc, Subsidiaries 29

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Callitas Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Callitas Therapeutics Inc (Callitas Therapeutics), formerly M Pharmaceutical Inc, is a drug discovery and development company that offers ground-breaking drug treatments and biomedical technologies. The company's products include weight management products, infertility products and women's healthcare products. It also provides comprising ToConceive, C-103 Reformulated Orlistat and Extrinsa. Callitas Therapeutics' products are used to improve the lives of people facing obesity, infertility and intimacy issues. The company's ToConceive is a fertility enhancing moisturizer that increases woman's own natural conception lubrication called transudate to aid in conception and Extrinsa address the lack of female sexual dysfunction solutions and focus on women with orgasm and arousal difficulties. Its topical, local, and non-systemic product is also non-hormonal and does not affect the central nervous system. Callitas Therapeutics is headquartered in Vancouver, British Columbia, Canada.

Callitas Therapeutics Inc (LILY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Callitas Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

M Pharma Acquires Assets from 40J's 12

M Pharma Acquires Orlistat Assets from Chelatexx 13

Partnerships 14

Callitas Health Enters into Partnership with NFI Consumer Healthcare 14

M Pharma to Form Joint Venture 15

Licensing Agreements 16

Callitas Health Recieves Intellectual Property from Ronald J. Thompson 16

M Pharma Enters into Licensing Agreement for Pediatric Orphan Drug 17

Equity Offering 18

M Pharma Raises USD0.03 Million in Private Placement of Units 18

M Pharma Raises USD0.7 Million in Private Placement of Units 19

M Pharma to Raise USD0.3 Million in Private Placement of Units 20

M Pharma Raises USD0.86 Million in Private Placement of Units 21

M Pharma Raises USD1 Million in Private Placement of Units 22

Acquisition 23

M Pharma Acquires ToConceive 23

M Pharma Plans to Acquire Pharma Company with an FDA Approved Women's Health Product 24

M Pharma Acquires Trimtec Biomedical 25

M Pharma Acquires RX Global Capital for USD1.9 Million 26

Callitas Therapeutics Inc-Key Competitors 27

Callitas Therapeutics Inc-Key Employees 28

Callitas Therapeutics Inc-Locations And Subsidiaries 29

Head Office 29

Other Locations & Subsidiaries 29

Recent Developments 30

Corporate Communications 30

Jun 07, 2018: James Thompson Elevated to President and Chief Executive Officer of Callitas Health 30

Jan 03, 2018: Callitas Announces New Interim CEO 31

Jun 08, 2017: M Pharmaceutical Appoints New Chief Financial Officer 32

Mar 03, 2017: M Pharmaceutical Appoints Kim Whittemore of San Diego, California to Its Board of Directors 33

Feb 21, 2017: M Pharmaceutical Appoints Mr. William A. Rodgers Jr., of Milton, Georgia to Its Board of Directors 34

Feb 13, 2017: M Pharmaceutical Appoints Mr. Gary Thompson President & CEO 35

Product News 36

Sep 29, 2017: ToConceive launches new paraben-free formula to promote natural conception 36

07/14/2017: M Pharmaceutical Provides Update on Extrinsa 37

Jan 24, 2017: M Pharmaceutical Announces Strategy To Seek Distribution Partners For Their Patented Technologies To Deliver Phytoestrogens For The Treatment Of The Symptoms Of Menopause 38

Jan 12, 2017: M Pharmaceutical Announces Plans to Develop a Drug Product for Treatment of Female Sexual Dysfunction 39

Product Approvals 40

Oct 11, 2017: Callitas Announces Positive FDA Response to Extrinsa Pre-IND Submission 40

Jul 18, 2017: M Pharmaceutical Plans to Submit Extrinsa PIND Meeting Request Letter and Package to US FDA 41

Other Significant Developments 42

Apr 19, 2018: Callitas Health Releases Annual Update Letter to Shareholders 42

Mar 13, 2018: Callitas Health Announces Selection Of TraDigitalIR As Investor And Public Relations Advisor 44

Mar 01, 2018: Callitas Health Has Big Plans For Broad Product Portfolio 45

Sep 15, 2017: M Pharmaceutical Announces Name Change to Callitas Health and Share Consolidation 47

Aug 01, 2017: M Pharmaceutical USA Announces a Change of Name to Callitas Therapeutics 48

Jul 07, 2017: M pharmaceutical reforecasts 2017 and 2018 revenues upward 49

Appendix 50

Methodology 50

About GlobalData 50

Contact Us 50

Disclaimer 50


List Of Figure

List of Figures

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Callitas Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Callitas Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Callitas Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Callitas Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

M Pharma Acquires Assets from 40J's 12

M Pharma Acquires Orlistat Assets from Chelatexx 13

Callitas Health Enters into Partnership with NFI Consumer Healthcare 14

M Pharma to Form Joint Venture 15

Callitas Health Recieves Intellectual Property from Ronald J. Thompson 16

M Pharma Enters into Licensing Agreement for Pediatric Orphan Drug 17

M Pharma Raises USD0.03 Million in Private Placement of Units 18

M Pharma Raises USD0.7 Million in Private Placement of Units 19

M Pharma to Raise USD0.3 Million in Private Placement of Units 20

M Pharma Raises USD0.86 Million in Private Placement of Units 21

M Pharma Raises USD1 Million in Private Placement of Units 22

M Pharma Acquires ToConceive 23

M Pharma Plans to Acquire Pharma Company with an FDA Approved Women's Health Product 24

M Pharma Acquires Trimtec Biomedical 25

M Pharma Acquires RX Global Capital for USD1.9 Million 26

Callitas Therapeutics Inc, Key Competitors 27

Callitas Therapeutics Inc, Key Employees 28

Callitas Therapeutics Inc, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Callitas Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.